–
Kairos Pharma, LTD.
Metrics score locked — part of Premium
FY21
FY22
FY23
FY24
FY25
FY21 – FY25
(positive)
millions USD
FY21:
FY22:
–
FY23:
–
FY24:
–
FY25:
–
(positive)
Change from FY21 to FY25
millions USD
FY21:
−1.94
FY22:
−0.57
FY23:
−1.71
FY24:
−2.34
FY25:
−5.57
(positive)
Change from FY21 to FY25
millions USD
FY21:
−1.88
FY22:
−0.43
FY23:
−1.55
FY24:
−2.85
FY25:
−5.29
(positive)
Change from FY21 to FY25
millions USD
FY21:
−2.15
FY22:
−1.05
FY23:
−1.81
FY24:
−2.60
FY25:
−5.45
(positive)
Change from FY21 to FY25
millions USD
FY21:
−2.15
FY22:
−1.05
FY23:
−1.81
FY24:
−2.60
FY25:
−5.45
All amounts in millions USD FY21, FY22: figures supplemented from Twelve Data because the SEC filings do not reach back this far.